MYELODYSPLASTIC SYNDROMES

This study tests a new way to prepare patients with leukemia or myelodysplastic syndromes for a donor stem cell transplant. It combines a precise type of radiation (helical tomotherapy) with two chemotherapy drugs (fludarabine and melphalan) to kill cancer cells and prevent rejec…

This study planned to test whether banked, frozen bone marrow from partially matched donors could be safely used for transplants in people with blood cancers like leukemia. Participants would have received a transplant followed by drugs to prevent graft-versus-host disease. The s…

This study tests whether giving a drug that changes how DNA is read (called a DNA methyltransferase inhibitor) before standard chemotherapy is safe and helps children with newly diagnosed acute myeloid leukemia. About 206 children will receive either azacitidine or decitabine for…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This study tests if luspatercept can help people with certain types of MDS or MDS/MPN need fewer blood transfusions for anemia. Six adults with low- or intermediate-risk disease and a specific gene mutation are receiving the drug plus standard care. The goal is to see if they can…

This study tests a drug called luspatercept in 70 adults with a low-risk form of MDS that causes severe anemia. The goal is to see if the drug can reduce or eliminate the need for regular red blood cell transfusions. Participants receive the drug by injection, and researchers tra…

This study tests a stem cell transplant using donors who are not a perfect match for people with blood cancers like leukemia or lymphoma. The goal is to see if adding certain drugs after the transplant can prevent complications and improve survival. About 300 adults and children …

This early-phase study tests a new way to do stem cell transplants for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors will give patients specially prepared immune cells (regulatory T-cells) along with regular dono…

This study tests a drug called eltrombopag in adults with a low-risk form of myelodysplastic syndromes (MDS) who regularly need platelet transfusions. The goal is to see if the drug can help patients go without transfusions for at least 8 weeks. The study involves 36 participants…

This study tests whether starting luspatercept at the highest approved dose can help people with low-risk myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 adults who currently need regular transfusions will receive the drug an…

This study tests a chemotherapy drug called CPX-351 in 20 adults aged 18-70 with high-risk myelodysplastic syndrome (MDS) who are eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable at two different dose levels. Researchers will also tra…

This study follows people with myelodysplastic syndromes or chronic myelomonocytic leukemia who already benefited from the drug sabatolimab in an earlier trial. The goal is to collect more safety information over time, not to test a new treatment. About 33 participants will conti…

This study tests a new drug called bexmarilimab, given with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The first part finds a safe dose, and the second part checks if the combination helps control the cancer. About 181 adults will take part.

This study tests a precise type of radiation (total marrow irradiation) given with standard chemotherapy before a stem cell transplant in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination helps more patie…

This study tests a combination of two drugs, canakinumab and darbepoetin alfa, in people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS) who no longer respond to standard treatment. The goal is to see if the combination is safe and can reduce…

This early-phase study tests whether the oral drug Inqovi (decitabine/cedazuridine) can safely reduce the chance of cancer returning after a stem cell transplant in people with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). About 22 adults who have had …

This study tests a special device that removes certain immune cells from donated blood stem cells before transplant. The goal is to lower the risk of graft-versus-host disease, a serious complication where the donor cells attack the patient's body. About 50 adults with myelodyspl…

This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug called ipilimumab. The main goal is to find…

This study tests whether a new drug called luspatercept works better than a standard drug (epoetin alfa) for treating anemia in adults with a certain type of bone marrow disorder called myelodysplastic syndromes (MDS). Participants have low-risk MDS, have not needed blood transfu…

This study tests an experimental drug called imetelstat in adults with a type of bone marrow cancer (MDS) who currently need regular blood transfusions and have stopped responding to standard treatments. The main goal is to see if the drug can help patients go 8 weeks or longer w…

This study tests whether stem cells from donated umbilical cords are safe and helpful for people with myelodysplastic syndrome (MDS), a bone marrow disorder. About 40 adults with moderate to severe MDS will receive the stem cells and be watched for side effects and improvements. …

This study provides continued treatment with the oral drug ASTX727 for adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in an earlier trial. The main goal is to gather long-term safety informatio…

This study tests whether an oral chemotherapy drug (azacitidine, also called ONUREG) can help people with a bone marrow disorder called myelodysplastic syndrome (MDS) that is low or intermediate risk. About 230 adults will receive either the drug or a placebo, along with standard…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like acute myeloid leukemia and myelofibrosis. The goal is to find the safest effective dose and see how well the combination wor…

This study tests an experimental drug called AG-946 in about 87 adults with anemia due to lower-risk myelodysplastic syndromes (MDS). The goal is to see if the drug can raise hemoglobin levels or help people go without blood transfusions for at least 8 weeks. Participants receive…

This study tests a new way to do stem cell transplants using cells from a half-matched family donor. By removing certain immune cells before transplant, researchers hope to lower the risk of graft-versus-host disease, a serious complication. The goal is to help patients with bloo…

This study compares an oral medication (ASTX727) to a standard IV drug for myelodysplastic syndromes (MDS), a bone marrow disorder. About 72 Chinese adults with MDS will receive both treatments in a crossover design to see if the pill works as well. The goal is to find a more con…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 3…

This early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for long-term immune-suppressing medications after a stem cell transplant. The trial involves 32 older adults (age 60+) with certain…

This study tests a program that combines mindfulness and music therapy, delivered through an app or website, for people undergoing a stem cell transplant. The goal is to see if it helps improve quality of life and reduce symptoms like pain. About 60 adults with certain blood canc…

This study looks at whether adding a palliative care team to standard leukemia care helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life planning. About 320 adults receiving non-intensive therapy will take part. …

This study looks at whether testing cancer cells in a lab can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers will collect blood samples from 80 adults before treatment and test them against diffe…

This study aims to find the genetic causes of blood and bone marrow cancers, such as leukemia. Researchers will look for specific cell abnormalities that drive cancer growth. Up to 5,000 people with these cancers will provide samples for analysis. The goal is to develop more effe…

This study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare stem cells from patients and healthy volunteers in the lab. However, the study was withdrawn before …

This study looks at how often people with certain blood cancers or related conditions have an acquired form of pyruvate kinase deficiency, a red blood cell enzyme problem. Researchers will take a single blood sample from 100 participants to check enzyme activity and gene changes.…

This study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study follows 300 people who have persistent low blood cell counts (anemia, low white cells, or low platelets) that cannot yet be diagnosed as a bone marrow disease called myelodysplastic syndromes (MDS). The goal is to track how often these patients progress to MDS or relat…

This study aims to better understand bone marrow failure disorders by analyzing genetic and protein changes in blood and bone marrow samples from up to 1,400 participants aged 2 and older, including healthy volunteers. Researchers hope to learn how these changes affect disease pr…

This study looks at how blood cancers and stem cell transplants impact muscle function in 144 patients. Researchers want to see if muscle problems can help predict complications like infections, hospital stays, or survival. The goal is to better understand recovery and guide futu…